CIBC Private Wealth Group
NTLA icon

CIBC Private Wealth Group’s Intellia Therapeutics NTLA Stock Holding History

CIBC Private Wealth Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$38.1K Buy
4,237
+152
+4% +$2.09K ﹤0.01% 1899
2025
Q3 		$70.5K Buy
4,085
+60
+1% +$739 ﹤0.01% 1637
2025
Q2 		$37.8K Sell
4,025
-646
-14% -$5.3K ﹤0.01% 1771
2025
Q1 		$29.3K Buy
4,671
+60
+1% +$606 ﹤0.01% 1840
2024
Q4 		$55.4K Sell
4,611
-3,771
-45% -$58.9K ﹤0.01% 1648
2024
Q3 		$172K Buy
8,382
+2,502
+43% +$57.7K ﹤0.01% 1261
2024
Q2 		$135K Buy
5,880
+1,299
+28% +$30.9K ﹤0.01% 1277
2024
Q1 		$125K Buy
+4,581
New +$127K ﹤0.01% 1302
2022
Q4 		– Sell
-4,324
Closed -$242K – 916
2022
Q3 		$242K Sell
4,324
-2,500
-37% -$155K ﹤0.01% 824
2022
Q2 		$353K Hold
6,824
– – ﹤0.01% 770
2022
Q1 		$496K Sell
6,824
-223
-3% -$18.9K ﹤0.01% 746
2021
Q4 		$833K Hold
7,047
– – ﹤0.01% 681
2021
Q3 		$945K Hold
7,047
– – ﹤0.01% 633
2021
Q2 		$1.14M Sell
7,047
-4,008
-36% -$312K ﹤0.01% 634
2021
Q1 		$887K Buy
11,055
+4,650
+73% +$312K ﹤0.01% 691
2020
Q4 		$348K Buy
+6,405
New +$233K ﹤0.01% 842
2018
Q3 		– Sell
-3,020
Closed -$83K – 1458
2018
Q2 		$83K Sell
3,020
-869
-22% -$21.1K ﹤0.01% 1062
2018
Q1 		$82K Buy
3,889
+889
+30% +$21.9K ﹤0.01% 1054
2017
Q4 		$58K Buy
+3,000
New +$69.3K ﹤0.01% 1142

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC Private Wealth Group's NTLA Position: Q4 2025 in Review

CIBC Private Wealth Group increased its Intellia Therapeutics (NTLA) stake by 3.7% in Q4 2025, buying an estimated $2.09K and bringing the position to 4,237 shares worth $38.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1899.

CIBC Private Wealth Group first reported a position in NTLA in Q4 2017 and has held it in 19 quarters since. The position peaked at $1.14M in Q2 2021. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • CIBC Private Wealth Group held 4,237 shares of Intellia Therapeutics worth $38.1K as of Q4 2025.
  • CIBC Private Wealth Group bought 152 Intellia Therapeutics shares in Q4 2025, an estimated $2.09K.
  • Intellia Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1899 holding.
  • CIBC Private Wealth Group first reported a position in Intellia Therapeutics in Q4 2017 and has held it in 19 quarters since.
  • CIBC Private Wealth Group's Intellia Therapeutics position peaked at $1.14M in Q2 2021.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.